Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers

• Status: Completed
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this trial is the caracterisation of a predicting algorithm of the answering response for patients with etanercept treatment in spondyloarthritis disease.

This algorithm will help to target patients patients who have a risk / benefit important for etanercept treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Grenoble
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• patients with spondylarthritis validating ASAS or New York modified critera, and for who etanercept is indicated.

• Naïve from biological Drug Modifying Anti Rheumatic Drugs

• patients between 18 and 70 years old

• patients who can be monitored at 6 months ;

• patients who can observe the entire treatment ;

• patiens with age to procreate under effective contraception ((abstinence, oral contraceptives , intrauterine devices , implants, spermicide or surgical sterilization ) during the study and for 6 months, 3 weeks after the last injection.

• patients able to understand and accept the terms of the study

• patients having signed the informed consent.

• patients insured under social security

Exclusion Criteria:

• patients of age protected ;

• patients with difficulties for understanding french language ;

• patients with high function disorders incompatible with an education program (dementia Alzheimer's type , etc ...) ;

• patients with psycho- social instability incompatible with regular monitoring (homeless , addictive behavior ,etc.) ;

• patients in a socio- professional situation incompatible with optimal attendance to the program - - Pregnant or nursing patients

• patients who received previously a biotherapy treatment . There is no other exclusion criteria taking into account previous treatments and the duration of them.

• contraindication to the use of anti- TNF treatment

• Surgery scheduled during the study.

• Persons mentioned in Articles L.1121-5 to L.1121-8 of the Public Health Code